0230: Effectiveness of switching Prasugrel's ‘low responders’ to ticagrelor after acute coronary syndrome
نویسندگان
چکیده
منابع مشابه
cost benefits of rehabilitation after acute coronary syndrome in iran; using an epidemiological model
چکیده ندارد.
Cost-Effectiveness Analysis of Ticagrelor and Prasugrel for the Treatment of Acute Coronary Syndrome.
BACKGROUND In the management of Asian patients with acute coronary syndrome (ACS), the comparative cost-effectiveness of ticagrelor and prasugrel, referenced to generic clopidogrel, is unknown. OBJECTIVE To assess the cost-effectiveness of ticagrelor and prasugrel as compared with generic clopidogrel in patients with ACS in Singapore. METHODS A Markov model simulating a typical cohort of 62...
متن کاملTicagrelor (brilinta), an antiplatelet drug for acute coronary syndrome.
Ticagrelor (Brilinta) for acute coronary syndrome.
متن کاملDyspnoea management in acute coronary syndrome patients treated with ticagrelor
The occurrence of dyspnoea in acute coronary syndrome (ACS) patients has always been considered a challenging diagnostic and therapeutic clinical scenario. P2Y12 platelet receptor inhibitors (i.e., clopidogrel, prasugrel and ticagrelor) are currently the cornerstone of treatment of ACS patients. Thus, in the last few years, the potential association between ACS and dyspnoea has also become more...
متن کاملCost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
INTRODUCTION Acute coronary syndrome is one of the most frequent medical emergencies in developing countries. OBJECTIVE To determine, from the perspective of the Colombian health system, the cost-effectiveness of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome. MATERIALS AND METHODS We conducted a cost-effectiveness analysis from the perspective...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Cardiovascular Diseases Supplements
سال: 2014
ISSN: 1878-6480
DOI: 10.1016/s1878-6480(14)71276-5